City Therapeutics (CTY) Raises $200 Million in IPO Before Any Human Data
As seen on the 24/7 Wall St. homepage on October 16, 2026.
Priced at $18, raising roughly $200 million
City Therapeutics priced at $18 a share, pulling in about $200 million for a preclinical RNAi platform with Goldman Sachs and Jefferies leading the book. That is one of the larger biotech raises of a record listing year, and it sets a fresh public market price on next-generation RNAi before any human data.
Continue ReadingShow less
City Therapeutics sold 11.1 million shares at $18 each, putting a firm public market valuation on an RNAi platform that has not yet dosed a human patient. That is a significant vote of confidence from institutional money, with Goldman Sachs and Jefferies running the books.
RNAi, or RNA interference, is a gene-silencing technology that directs the body's own machinery to shut off disease-causing genes before they produce harmful proteins. The commercial promise is substantial, but so is the risk: City Therapeutics is preclinical, meaning investors are pricing in a long runway of development before any trial readout could validate the approach.
The $200 million raise stands out even in what the filing context describes as a record year for biotech listings. Pulling in that much capital without clinical data signals that lead investors see the platform itself as the asset. The stock will be especially sensitive to any early pipeline update.
Goldman Sachs and Jefferies bringing this deal to market at scale suggests strong institutional demand at the $18 clearing price. Investors who did not get allocations in the book-building process will be watching the first days of trading on Nasdaq closely to see whether that demand holds, fades, or attracts fresh buyers once the stock is freely tradable.
Mentioned: CTY